Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Analysis of Liquidity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Analysis of Geographic Areas
- Enterprise Value to EBITDA (EV/EBITDA)
- Enterprise Value to FCFF (EV/FCFF)
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Selected Financial Data since 2005
- Return on Assets (ROA) since 2005
- Price to Operating Profit (P/OP) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
- Gross Profit Margin
- The gross profit margin remained relatively stable over the recorded periods, ranging mostly between approximately 84.6% and 87.2%. There is a slight downward trend from the peak at 87.18% in March 2023 to 85.79% by March 2025, indicating a minor reduction in the company's ability to maintain production costs relative to revenue. However, overall margin levels suggest consistently strong profitability at the gross level.
- Operating Profit Margin
- The operating profit margin showed notable fluctuations. It initially increased from 42.09% in March 2021 to a peak of 55.67% in March 2022, demonstrating significant operational efficiency improvements during this period. Post-peak, the margin declined steadily, reaching 27.2% by March 2025. This downward trend suggests rising operating expenses or challenges in sustaining prior efficiency levels, potentially affecting operating income generation.
- Net Profit Margin
- The net profit margin followed a comparable pattern to the operating margin. It rose from 41.35% in March 2021 to a high of 51.65% in December 2021, then progressively decreased to 31.94% by March 2025. The decline after the peak indicates growing pressures on overall profitability after accounting for all expenses, taxes, and other factors, though the margins remain relatively healthy.
- Return on Equity (ROE)
- The ROE reached its highest values between September 2021 and March 2022, peaking around 43.03%. Following this, a clear declining trend is observed, with ROE dropping to approximately 15.31% by March 2025. This reduction in ROE over time may reflect lower net income relative to shareholders’ equity, possibly due to decreased profitability or an increase in equity base.
- Return on Assets (ROA)
- ROA mirrored the general trend of ROE, with peak returns near 31.75% in March 2022. Subsequently, ROA declined gradually, settling near 11.98% by March 2025. This decline suggests less efficient use of assets in generating net income over time, potentially attributable to higher asset base growth or reduced earnings efficiency.
Return on Sales
Return on Investment
Gross Profit Margin
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
Gross profit | ||||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||
Gross profit margin1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Gross profit margin = 100
× (Gross profitQ1 2025
+ Gross profitQ4 2024
+ Gross profitQ3 2024
+ Gross profitQ2 2024)
÷ (RevenuesQ1 2025
+ RevenuesQ4 2024
+ RevenuesQ3 2024
+ RevenuesQ2 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The gross profit and revenue figures exhibit noticeable fluctuations over the observed periods, with some intervals showing marked increases and others a decline.
- Gross Profit Trends
- From the first quarter of 2020 through the fourth quarter of 2021, gross profit shows a general upward trajectory, rising from approximately 1.61 billion US dollars to nearly 3.97 billion US dollars, reflecting substantial growth. However, from 2022 onwards, gross profit values exhibit volatility without a consistent trend, peaking in the third quarter of 2024 at around 3.23 billion US dollars before decreasing sharply to approximately 2.56 billion US dollars by the first quarter of 2025.
- Revenue Trends
- Revenues follow a broadly similar pattern to gross profit but with amplified variability, starting at approximately 1.83 billion US dollars in early 2020 and spiking to over 5.13 billion US dollars in the second quarter of 2021. This peak is followed by declines and recoveries, with revenues dropping to around 2.85 billion US dollars mid-2022, then gradually increasing to about 3.79 billion US dollars in the fourth quarter of 2024, before falling back to approximately 3.03 billion US dollars in the first quarter of 2025.
- Gross Profit Margin
- The gross profit margin, available from the first quarter of 2021 onwards, remains relatively stable, fluctuating narrowly between approximately 84.6% and 87.2%. This suggests consistent operational efficiency and cost management relative to revenues, despite the volatility in absolute revenue and gross profit figures.
- Observations and Insights
- The significant spikes in revenues and gross profit in mid-2021 indicate possible extraordinary events such as large product launches, acquisitions, or other business expansions. Post that period, the variability might point to market adjustments or changes in product demand.
- The roughly stable gross profit margin reflects the company’s ability to maintain profitability proportionally to revenues across varying market conditions. The decline in both gross profit and revenues towards early 2025 warrants monitoring, as it may signal emerging challenges or cyclical factors affecting the company’s performance.
Operating Profit Margin
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
Income from operations | ||||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||
Operating profit margin1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Operating profit margin = 100
× (Income from operationsQ1 2025
+ Income from operationsQ4 2024
+ Income from operationsQ3 2024
+ Income from operationsQ2 2024)
÷ (RevenuesQ1 2025
+ RevenuesQ4 2024
+ RevenuesQ3 2024
+ RevenuesQ2 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The income from operations displays considerable volatility over the observed periods. It begins in early 2020 with a moderate scale and experiences a substantial peak in the mid-2021 quarter, reaching the highest level across the timeframe. This spike is followed by fluctuations with a general declining trend from late 2021 through early 2025, culminating in a notably lower value in the first quarter of 2025 compared to its peak.
Revenues exhibit a broadly upward trajectory with intermittent phases of rapid growth and temporary declines. An initial rising trend is evident from early 2020 to late 2021, marked by a pronounced increase around mid-2021. Subsequent quarters reveal some fluctuations but maintain an overall growth pattern, reaching peak revenue figures between late 2023 and late 2024. However, a downturn is observed at the beginning of 2025.
Operating profit margin percentages, available from late 2020 onwards, reveal a descending trend. Initially, the margins are relatively high, exceeding 50% in several quarters during 2021. Afterward, a persistent decline occurs, dropping steadily through 2022, 2023, and into 2024, ending at just over 27% by the first quarter of 2025. This indicates decreasing efficiency or increasing costs relative to revenues over these periods.
- Income from Operations
- Highly variable with a significant peak in mid-2021 followed by a downward trend.
- Revenues
- Overall growth with spikes and fluctuations, peaking around late 2023 to late 2024, followed by a decline at the start of 2025.
- Operating Profit Margin
- Strong margins initially above 50% in 2021, steadily decreasing thereafter to approximately 27% by early 2025.
In summary, the financial data suggest that while revenue growth has generally been positive, operating profitability relative to those revenues has diminished over time. This decline in profit margins indicates challenges in managing operating costs or other factors impacting operational efficiency despite substantial revenue increases during peak periods.
Net Profit Margin
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
Net income | ||||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||
Net profit margin1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Net profit margin = 100
× (Net incomeQ1 2025
+ Net incomeQ4 2024
+ Net incomeQ3 2024
+ Net incomeQ2 2024)
÷ (RevenuesQ1 2025
+ RevenuesQ4 2024
+ RevenuesQ3 2024
+ RevenuesQ2 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
Over the observed periods, net income exhibits notable fluctuations with distinct peaks and troughs. Initially, from early 2020 to the end of 2021, net income generally increased, reaching a high in the second quarter of 2021. Following this peak, there is a decline in net income through most of 2022, with some recovery towards the end of 2022 and into 2023. However, net income again shows variability in 2023 and early 2024, with a marked decline in the first quarter of 2025 compared to the previous quarters.
Revenues demonstrate an overall upward trend through late 2021, peaking sharply in the second quarter of 2021. After this peak, revenues decline through much of 2022 but exhibit some stabilization and moderate growth from late 2022 through 2024. Nevertheless, quarterly revenue remains somewhat volatile, and there is a notable downturn in revenue in the first quarter of 2025 compared to the preceding quarters.
The net profit margin data, available from late 2020 onward, reveals a generally decreasing trend over the entire period. Margins peak around the final quarter of 2020 and early 2021, remaining above 40% during this phase. From that point onward, net profit margin experiences a gradual decline, falling below 35% by 2023 and continuing into the low 30% range during 2024 and early 2025. Despite some minor fluctuations, the trend indicates a compression of profitability relative to revenues over time.
- Net Income
- Increased significantly up to mid-2021, followed by cyclical declines and recoveries; the first quarter of 2025 shows a decrease compared to previous quarters.
- Revenues
- Overall upward trajectory with a sharp peak in mid-2021, then declining through 2022; moderate recovery and stabilization observed afterward, yet ending with a downturn in early 2025.
- Net Profit Margin
- Peaked above 40% in late 2020 and early 2021, then steadily declined through 2023 and 2024 to around 30-33% in early 2025, suggesting decreasing efficiency or increased costs impacting profitability.
In summary, the data indicates that while the company experienced strong growth in both net income and revenues up to mid-2021, subsequent periods have been characterized by volatility and a general decline in profit margins. The persistent reduction in net profit margin suggests rising costs or margin pressures despite revenue fluctuations, which may warrant closer financial management or strategic adjustments moving forward.
Return on Equity (ROE)
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
Net income | ||||||||||||||||||||||||||||
Stockholders’ equity | ||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||
ROE1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
ROE, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
ROE = 100
× (Net incomeQ1 2025
+ Net incomeQ4 2024
+ Net incomeQ3 2024
+ Net incomeQ2 2024)
÷ Stockholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of the financial data reveals several key trends and patterns concerning net income, stockholders’ equity, and return on equity (ROE) over the periods from March 2020 to March 2025.
- Net Income
- Net income exhibits notable volatility across the quarters under review. In 2020, net income showed a general increase, reaching a peak of 1,149,200 thousand USD in December 2020 after rising from 624,600 thousand USD in March 2020. The first half of 2021 saw a significant surge, with net income jumping to 3,098,900 thousand USD in June 2021, the highest in the dataset, followed by a decline in subsequent quarters.
- From the third quarter of 2021 through 2022, net income stabilized around a range of approximately 850,000 to 1,300,000 thousand USD, with some fluctuations. In 2023, net income generally remained below the highs of 2021, with values typically between 800,000 and 1,159,600 thousand USD, indicating a more moderate earnings environment.
- Entering 2024 and beyond, net income again showed variability but with a slight downward trend, culminating in 808,700 thousand USD by March 2025, which is significantly lower compared to the mid-2021 peak. This pattern suggests some cyclical or event-driven factors influencing profitability.
- Stockholders’ Equity
- Stockholders’ equity demonstrates a steady upward trajectory over the entire period analyzed. A minor dip is observed between March and June 2020, where equity decreased from approximately 12,133,000 thousand USD to 9,057,400 thousand USD, possibly reflecting external market or operational impacts.
- After mid-2020, equity consistently increased quarter-over-quarter, rising from around 10,125,500 thousand USD in September 2020 to over 29,387,600 thousand USD by March 2025. This consistent growth reflects a strong accumulation of retained earnings, reinvestment, or capital inflows enhancing the company’s equity base.
- The persistent equity growth contrasts with the volatility observed in net income, indicating effective capital management and an increasing asset base or shareholder value over time.
- Return on Equity (ROE)
- The ROE values are available from March 2021 onwards and illustrate a generally declining trend throughout the period. The highest ROE was recorded in September 2021 at 41.02%, reflecting an exceptionally profitable quarter relative to equity.
- Following this peak, ROE gradually decreased, settling into a lower range in the late 2023 to 2025 quarters, fluctuating mostly between 14% and 19%. The decline in ROE, despite rising equity and varying net income, indicates that net income growth has not kept pace proportionally with the increase in equity.
- This pattern suggests diminishing efficiency in utilizing equity to generate profits or normalization after a period of unusually high earnings.
In summary, the data suggests strong and steady growth in stockholders’ equity, marked fluctuations and cyclical patterns in net income with seasonal or event-related peaks, and a declining trend in return on equity, indicating that while the firm continues to grow its equity base, its profitability relative to that equity has moderated over time.
Return on Assets (ROA)
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
Net income | ||||||||||||||||||||||||||||
Total assets | ||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||
ROA1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
ROA, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
ROA = 100
× (Net incomeQ1 2025
+ Net incomeQ4 2024
+ Net incomeQ3 2024
+ Net incomeQ2 2024)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The net income exhibits notable fluctuations throughout the periods observed. Initially, there is a strong upward trend from March 2020 to June 2021, peaking significantly in June 2021 at 3,098,900 thousand USD. Following this peak, net income generally declines, with intermittent rises, yet does not reach the earlier highs, ending at 808,700 thousand USD in March 2025. This pattern indicates periods of substantial profitability followed by moderation.
Total assets demonstrate a consistent upward trajectory over the entire timeframe. Beginning at 15,757,500 thousand USD in March 2020, total assets increase steadily and reach a level of approximately 37,545,200 thousand USD by March 2025. This growth suggests ongoing expansion and accumulation of resources or investments within the company.
The Return on Assets (ROA) presents a decrease from relatively high figures in early 2021, starting at 20.47% in March 2021 and rising to a peak of 31.75% in March 2022. After this peak, ROA declines continuously, stabilizing in the range of approximately 11-14% from mid-2022 onwards. This decline may indicate reduced efficiency in generating net income from the asset base or an increase in assets not yet translating proportionately into earnings.
- Net Income
- Sharp increase until mid-2021 followed by a gradual decline; variability reflects changing profitability trends.
- Total Assets
- Consistent and substantial growth over the full period, reflecting asset accumulation and likely investment or expansion activities.
- Return on Assets (ROA)
- High values early in the observed period with a notable peak in early 2022, followed by a steady decrease, indicating a possible decline in asset utilization efficiency.
Overall, the financial data suggest a phase of rapid growth and high profitability up to mid-2021, with asset growth maintained throughout the observed periods. However, efficiency in utilizing these assets to generate profits, as indicated by the ROA, has diminished after peaking, which could warrant further investigation into operational or market factors affecting profitability.